Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) announced the appointment of Eran Kuratz as head of supply chain and business process administration for its wholly owned subsidiary, Scinai Biopharma Services Ltd. Kuratz brings over 30 years of leadership and operational experience across pharmaceutical, biotechnology, medical-device, and industrial sectors. His responsibilities will include procurement, contracting, inventory management, logistics, budgeting, IT and business systems, cybersecurity, and cross-functional business processes.
This appointment comes on the heels of Scinai's expansion of its contract development and manufacturing organization (CDMO) platform through the first-quarter 2026 acquisition of Recipharm Israel, which added a second development and manufacturing site in Yavne. Combined with Scinai's Jerusalem operations, the expanded platform now provides a comprehensive range of capabilities, including biologics process development, aseptic manufacturing, sterile fill-and-finish, small-molecule active pharmaceutical ingredient (API) development and synthesis, analytical-method development, and GMP manufacturing.
The strategic move positions Scinai to better serve the growing demand for CDMO services, particularly in the biotech and pharmaceutical sectors. With the integration of Recipharm Israel, Scinai now offers a broader spectrum of services, enabling it to cater to clients at various stages of drug development and manufacturing. The appointment of Kuratz is expected to streamline operations and enhance efficiency across the expanded platform, ensuring robust supply chain management and business process administration.
Kuratz's extensive experience will be instrumental in overseeing the complex logistics and operational demands of a multi-site CDMO. His leadership in supply chain and business processes is likely to drive cost efficiencies, improve turnaround times, and maintain high standards of quality and compliance, which are critical in the highly regulated pharmaceutical industry.
The CDMO market has been experiencing significant growth, driven by the increasing outsourcing of manufacturing by biotech and pharma companies. By strengthening its operational leadership, Scinai aims to capitalize on this trend and compete effectively with established CDMO players. The expansion and leadership appointment align with Scinai's broader strategy to leverage its capabilities in both biologics and small molecules, offering a one-stop-shop for clients seeking development and manufacturing services.
Scinai Immunotherapeutics is a biopharmaceutical company focused on developing innovative immunology therapies. Its pipeline includes therapeutic candidates licensed from the Max Planck Society and PinCell S.r.l. The company also owns Scinai Biopharma Services Ltd., which provides CDMO services through its facilities in Jerusalem and Yavne, Israel. For more information on the full press release, visit https://ibn.fm/d9ktl. The latest news and updates regarding Scinai are available at https://ibn.fm/SCNI.
